A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Sponsor: Novartis Vaccines
A PHASE3 clinical study on Meningitis, Meningococcal, this trial is completed. The trial is conducted by Novartis Vaccines and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Vaccines
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States , Alvear 1439 PB Dpto, Rio IV, Cordoba, Argentina , Annapolis, United States , Aurora, United States , Baltimore, United States , Bardstown, United States , Bessemer, United States , Birmingham, United States , Boardman, United States , Boston, United States and 46 more locations